Skip to main content
INAB logo

INAB · In8bio, Inc.

Track INAB — free
$1.07 -0.03 (-2.73%) At close · Sep 11
Market Cap
$10.55M
Shares
9.86M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.07 Open$1.12 Day$1.06–1.13 52W close$0.96–2.59 Avg vol 30d62K Short int91K · 0.9% float · 1.6d Short vol16% Last earningsMay 21, 2026 DataJun 2025–Sep 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Jun 6, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
May 25, 2028 Est · unconfirmed · in 89 wks
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
Trailing 12 months
Net income (TTM)
−$18.67M
Trailing 12 months
Revenue growth YoY
Year over year
Operating margin
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
$18.13M
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+372.6%
Year over year · more shares
Price change (1Y)
-48.8%
Trailing year
Short interest
0.9%
Latest settlement · 1.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −9%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 7%
near low
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −47%
trailing
YTD return −54%
this year
Relative strength −64%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.92% of float · ▼ -35.1% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
21 holders — mid 3-yr range
Squeeze score 29
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 85%
annualized · 1-yr
Max drawdown −63%
past year
ATR 7.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
7% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.92% of float · ▼ -35.1% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
21 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 7% Range high $3
vs 200-day avg -33% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INAB
In8bio, Inc.
this stock
$10.55M -54.3% 0.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
$130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
$61.22B +17.1% 2.0%
MRNA
Moderna, Inc.
$57.48B +388.2% +4.3% 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
21
% held
38.4%
Net QoQ
+37.0K sh
Top holder
Alyeska Investment Group,…
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Falling
Shares short
90.8K
Days to cover
1.6d
Change
-49.1K sh
View
Short Volume
Short vol %
16%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
607
Value
$716
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
58.8%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-19.4M
EPS diluted
$-4.44
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
10
View
Exempt Offerings
Offering
$40.2M
Filed
Dec 30, 2025
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 14, 2026
Last call
May 21, 2026
View
Investor Relations
Latest news
IN8bio to Present at H.C. Wainwri…
Published
Sep 10, 2026
Upcoming events
1
View

Performance

Raw-price comparisons begin at the captured split on Jun 6, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
INAB -7.8% -9.3% -46.5% -2.7% -54.3%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -6.6% -7.6% -64.3% -2.4% -66.4%
Key facts CIK 1740279 CUSIP 45674E208 13F (30d) 7 filings 7 filers Visit website Investor relations